Molecular Diagnostics Market Set To Grow To $11bn By 2021

14 August 2018
Pharma

Visiongain has launched a new pharma report The Molecular Diagnostics (MDx) Market Forecast 2017-2027: Infectious Disease Testing, Oncology Testing, Blood Screening, Genetic Testing, Tissue Typing

Molecular diagnostics is a fast-growing and rapidly evolving sector of the IVD market, made possible by the growing understanding of the human genome. Molecular diagnostics tests have also led to the emerging field of companion diagnostics, in which a MDx test is used to identify whether a specific therapy is likely to be effective for an individual patient. The market for MDx is growing rapidly due to increasing biomarker discover and adoption rates, but its growth is limited by several regulatory and reimbursement issues.

The lead analyst of the report commented “There will be increasing adoption of molecular diagnostics over the forecast period as the benefits of increasing accuracy and speed of diagnosis become increasingly apparent. Another driver for the MDx industry will be the advent of Point-Of-Care MDx testing, which will greatly increase the potential availability of molecular testing as it moves out of high and moderate complexity laboratories into primary care settings such as hospitals and physicians’ offices.

The advent of personalised healthcare is also being driven by molecular diagnostics, as the ability to better stratify patients with added genetic information will allow physicians to select treatments that have a higher chance of success in an individual patient, as well as allowing for more detailed monitoring and evaluation of disease progression”

Leading companies featured in the report include Roche Diagnostics, Qiagen, Hologic, bioMérieux, Agilent Technologies, Becton, Dickinson & Company,

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Pharmaceutical CDMO Services on the Rise

The pharmaceutical market is one of today’s fastest-growing industries, which is why the professionals from Visiongain have made it their business to help companies and stakeholders stay up to date. One sector experiencing significant growth is that of contract development and manufacturing organization (CDMO) services. Here you’ll find all you need to know about this fast-growing sector of the pharmaceutical …

24 February 2020

Read

“Global Cell Therapy Technologies market set to grow to $23bn by 2024” says new Visiongain report

Cell therapy technologies are used across various research areas including gene therapy, cancer vaccines, regenerative medicine, biologics and others. Increasing global disease burdens and the need for more personalised & precision medicine has led to massive growth in the cell technology market, which is likely to increase over the next decade.

19 February 2020

Read

“Global Asthma & COPD market set to grow to $49 bn by 2025” says new Visiongain report

The Asthma and COPD market has the potential to bring several blockbuster drugs to the marketplace due to the increasingly segmented sub-groups of patients.

17 February 2020

Read

“Global Rheumatoid Arthritis Drugs market estimated to grow at a CAGR of 0.6% in the second half of the forecast period” says Visiongain report

Another factor driving the growth in the market is the discovery of new molecules that are involved in the disease process, and hence, new strategies for treating the disease.

17 February 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever